BDC -1001 is an immune stimulating antibody conjugate (ISAC) that combines a tumour-targeting antibody with an immune-stimulating payload, and it is being investigated in a phase I/II trial in combination with nivolumab in all solid tumours with HER2 OE or AMP, including NSCLC (NCT04278144). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.